S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
S&P 500   3,258.59 (+0.37%)
DOW   26,853.30 (+0.14%)
QQQ   268.10 (+1.02%)
AAPL   110.19 (+1.82%)
MSFT   206.09 (+1.43%)
FB   251.08 (+0.62%)
GOOGL   1,425.01 (+0.15%)
AMZN   3,040.33 (+0.68%)
TSLA   404.70 (+4.36%)
NVDA   504.21 (+2.08%)
BABA   267.34 (-0.89%)
CGC   14.00 (-1.89%)
GE   6.03 (-0.50%)
MU   48.34 (-2.28%)
AMD   76.44 (+0.82%)
T   27.77 (-0.96%)
F   6.53 (-1.95%)
ACB   4.99 (-4.04%)
GILD   61.91 (-0.55%)
NFLX   476.59 (+0.74%)
DIS   122.22 (-0.22%)
BAC   23.22 (-0.51%)
BA   150.71 (+3.19%)
Log in
NASDAQ:ALVR

Allovir Stock Forecast, Price & News

$28.24
+2.21 (+8.49 %)
(As of 09/25/2020 11:44 AM ET)
Add
Compare
Today's Range
$24.60
Now: $28.24
$28.47
50-Day Range
$21.05
MA: $30.25
$42.70
52-Week Range
$18.15
Now: $28.24
$45.28
Volume9,129 shs
Average Volume451,852 shs
Market Capitalization$609.28 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALVR
CUSIPN/A
CIKN/A
Phone617-433-2605

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees20
Market Cap$609.28 million
Next Earnings Date12/2/2020 (Estimated)
OptionableNot Optionable
$28.24
+2.21 (+8.49 %)
(As of 09/25/2020 11:44 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALVR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Allovir (NASDAQ:ALVR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Allovir?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allovir in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Allovir
.

When is Allovir's next earnings date?

Allovir is scheduled to release its next quarterly earnings announcement on Wednesday, December 2nd 2020.
View our earnings forecast for Allovir
.

How were Allovir's earnings last quarter?

Allovir (NASDAQ:ALVR) released its quarterly earnings data on Wednesday, September, 2nd. The company reported ($4.43) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $4.12.
View Allovir's earnings history
.

What price target have analysts set for ALVR?

4 Wall Street analysts have issued 1 year price targets for Allovir's stock. Their forecasts range from $41.00 to $50.00. On average, they anticipate Allovir's stock price to reach $46.67 in the next year. This suggests a possible upside of 65.3% from the stock's current price.
View analysts' price targets for Allovir
.

Who are some of Allovir's key competitors?

What other stocks do shareholders of Allovir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allovir investors own include Johnson & Johnson (JNJ), Coca-Cola (KO), Regeneron Pharmaceuticals (REGN), Axon Enterprise (AAXN), Abbott Laboratories (ABT), Appian (APPN), Alteryx (AYX), Boeing (BA), Biohaven Pharmaceutical (BHVN) and Carnival (CCL).

Who are Allovir's key executives?

Allovir's management team includes the following people:
  • Mr. David L. Hallal, Chairman & CEO (Age 54)
  • Mr. Vikas Sinha, Pres, CFO & Director (Age 57)
  • Mr. Brett R. Hagen, Chief Accounting Officer (Age 47)
  • Dr. Ann M. Leen Ph.D., Chief Scientific Officer (Age 44)
  • Mr. Edward Miller, Gen. Counsel (Age 55)

When did Allovir IPO?

(ALVR) raised $252 million in an initial public offering on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is Allovir's stock symbol?

Allovir trades on the NASDAQ under the ticker symbol "ALVR."

When did Allovir's quiet period expire?

Allovir's quiet period expired on Tuesday, September 8th. Allovir had issued 16,250,000 shares in its IPO on July 30th. The total size of the offering was $276,250,000 based on an initial share price of $17.00. During Allovir's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Allovir?

Shares of ALVR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allovir's stock price today?

One share of ALVR stock can currently be purchased for approximately $28.24.

How big of a company is Allovir?

Allovir has a market capitalization of $609.28 million. Allovir employs 20 workers across the globe.

What is Allovir's official website?

The official website for Allovir is www.allovir.com.

How can I contact Allovir?

Allovir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-433-2605 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.